Jason Eckel, MD
Nephrology · Cary, NCNPI 1801079884
Payments from drug & device makers
Across 585 payments — averaging $866.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$208K
- CSL Behring$170K
- Otsuka America Pharmaceutical, Inc.$66K
- AstraZeneca$36K
- Lundbeck LLC$9K
- Biogen$7K
- plus $12K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 8 | $207,650 |
| CSL Behring | 41 | $169,880 |
| Otsuka America Pharmaceutical, Inc. | 153 | $66,185 |
| AstraZeneca(2 entities) | 102 | $36,040 |
| Lundbeck LLC | 16 | $8,514 |
| Biogen | 2 | $6,822 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $4,148 |
| Calliditas Therapeutics US Inc. | 14 | $2,730 |
| Amgen(2 entities) | 55 | $1,172 |
| Fresenius USA Marketing, Inc. | 47 | $960 |
| Akebia Therapeutics Inc | 18 | $416 |
| Vifor Pharma, Inc. | 14 | $307 |
| Bayer | 11 | $237 |
| OPKO Pharmaceuticals, LLC | 10 | $207 |
| Mallinckrodt Hospital Products Inc. | 8 | $195 |
| Travere Therapeutics, Inc. | 13 | $186 |
| GSK | 10 | $178 |
| Novo Nordisk | 8 | $173 |
| Ardelyx, Inc. | 8 | $160 |
| Novartis | 9 | $149 |
| Aurinia Pharma U.S., Inc. | 6 | $113 |
| Sanofi | 5 | $90 |
| Alnylam Pharmaceuticals Inc. | 3 | $85 |
| Mallinckrodt Enterprises LLC | 3 | $61 |
| Boehringer Ingelheim | 3 | $57 |
| Boston Scientific | 1 | $50 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$506,948 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Cary
- Daniel EdmonstonDurham$9.9M
- Gregory GreenwoodWinston-Salem$4.1M
- Barry FreedmanWinston Salem$3.5M
- Manuel MonteroNew Bern$2.5M
- Rekha JohnKinston$2.3M
- Nauman ShahidGreenville$2M
- Eric KirkWilmington$1.7M
- Amy MottlSanford$1.6M
- Amarnath KathresalDurham$1.6M
- Koithara Varkey ThomasJacksonville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.